The biological basis of a comprehensive grading system for the adverse effects of cancer treatment
- PMID: 12903008
- DOI: 10.1016/S1053-4296(03)00045-6
The biological basis of a comprehensive grading system for the adverse effects of cancer treatment
Abstract
As described in the previous article in this issue by Trotti et al, there have been major changes in the philosophy and scope of the new National Cancer Institute comprehensive grading system for treatment-related toxicities, Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0). The most prominent changes are the merging of early and late effects criteria into a single uniform document and the development of criteria that cover all treatment modalities. In this article, we briefly outline the biological support for the new grading system in the context of our current knowledge base. The clinical consequences of radiotherapy in normal tissue have been classically grouped temporally, into early and late effects, using a somewhat arbitrary dividing line, 90 days after commencement of radiotherapy. This definition was developed in an era of standard fractionation used alone or in simple sequential programs involving other modalities. However, most patients are now managed with multiple highly integrated modalities, often augmenting tissue injury and limiting our ability to ascribe any given effect to a particular modality. The use of complex concurrent or hybrid (concurrent/sequential) schedules also undermines the usefulness of a simplistic temporally defined early-late construct. Moreover, there is growing recognition that chemotherapy and surgery produce inherent long-term biologic and clinical effects as well. Our basic understanding of the roles that surgery, chemotherapy, and radiation play in normal tissue response has expanded over the last decade because of vastly improved molecular techniques. The original biologic paradigm viewing acute and late tissue injury as a continuum of response and repair has been strengthened by these additional laboratory investigations. The expression of toxicity over time has been shown to be caused by a variety of cellular, tissue, environmental, and host factors. We continue to elucidate the roles of DNA damage, cytokines, chemokines, and associated inflammation, which lead in some cases to perpetuation of the wound-healing response, progressive tissue fibrosis, and vascular compromise. The continuum model of tissue injury supports the recent changes in the common toxicity grading system. It also provides insights into potential targets and strategies for modulating response, which may in turn lead to effective interventions for altering the therapeutic ratio.
Similar articles
-
Normal tissue effects: reporting and analysis.Semin Radiat Oncol. 2003 Jul;13(3):189-202. doi: 10.1016/S1053-4296(03)00036-5. Semin Radiat Oncol. 2003. PMID: 12903009 Review.
-
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.Semin Radiat Oncol. 2003 Jul;13(3):176-81. doi: 10.1016/S1053-4296(03)00031-6. Semin Radiat Oncol. 2003. PMID: 12903007 Review.
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
-
Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1129-39. doi: 10.1016/j.ijrobp.2005.09.017. Epub 2006 Jan 18. Int J Radiat Oncol Biol Phys. 2006. PMID: 16414206 Clinical Trial.
-
Adverse event reporting and developments in radiation biology after normal tissue injury: International Atomic Energy Agency consultation.Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1442-51. doi: 10.1016/j.ijrobp.2005.10.014. Epub 2006 Jan 18. Int J Radiat Oncol Biol Phys. 2006. PMID: 16414207
Cited by
-
Symptom clusters in patients with head and neck cancer receiving concurrent chemoradiotherapy.Oral Oncol. 2013 Apr;49(4):360-6. doi: 10.1016/j.oraloncology.2012.10.004. Epub 2012 Nov 17. Oral Oncol. 2013. PMID: 23168337 Free PMC article.
-
Hypofractionated dose-painting intensity modulated radiation therapy with chemotherapy for nasopharyngeal carcinoma: a prospective trial.Int J Radiat Oncol Biol Phys. 2011 May 1;80(1):148-53. doi: 10.1016/j.ijrobp.2010.01.026. Epub 2010 Jun 3. Int J Radiat Oncol Biol Phys. 2011. PMID: 20605352 Free PMC article. Clinical Trial.
-
Prevention of radiation dermatitis with skin hygiene and washing: a systematic review and meta-analysis.Support Care Cancer. 2023 Apr 22;31(5):294. doi: 10.1007/s00520-023-07720-8. Support Care Cancer. 2023. PMID: 37086339
-
The effects of low-dose radiation therapy in patients with mild-to-moderate Alzheimer's dementia: an interim analysis of a pilot study.Radiat Oncol J. 2023 Jun;41(2):89-97. doi: 10.3857/roj.2023.00052. Epub 2023 Jun 26. Radiat Oncol J. 2023. PMID: 37403351 Free PMC article.
-
Ophiopogon japonicus inhibits radiation-induced pulmonary inflammation in mice.Ann Transl Med. 2019 Nov;7(22):622. doi: 10.21037/atm.2019.11.01. Ann Transl Med. 2019. PMID: 31930023 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials